Frank H J Van Den Hoogen

List of Publications by Year
in descending order

107 papers	10,728 citations	109321 35 h-index	33894 99 g-index
109 all docs	109 docs citations	109 times ranked	10524 citing authors

#	Article	IF	Citations
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
3	The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism, 2000, 43, 155-163.	6.7	1,250
4	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
5	The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 1831-1835.	6.7	573
6	Mortality in systemic sclerosis: An international meta-analysis of individual patient data. American Journal of Medicine, 2005, 118, 2-10.	1.5	419
7	Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415
8	Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Research, 2002, 4, 87.	2.0	303
9	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open–Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology, 2018, 70, 60-68.	5.6	142
10	Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1503-1507.	0.9	136
11	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ, The, 2015, 350, h1389-h1389.	6.0	135
12	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. Journal of Rheumatology, 2009, 36, 2164-2170.	2.0	120
13	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy. Arthritis and Rheumatism, 2001, 44, 754-760.	6.7	110
14	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
15	Unraveling SSc Pathophysiology; The Myofibroblast. Frontiers in Immunology, 2018, 9, 2452.	4.8	103
16	Open–Label, Non–Mandatory Transitioning From Originator Etanercept to Biosimilar <scp>SB</scp>4. Arthritis and Rheumatology, 2018, 70, 1408-1418.	5.6	90
17	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1849-1854.	0.9	88
18	Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 775-782.	6.7	86

#	Article	IF	Citations
19	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs, 2018, 32, 397-404.	4.6	82
20	Validation of potential classification criteria for systemic sclerosis. Arthritis Care and Research, 2012, 64, 358-367.	3.4	77
21	Improved insulin sensitivity by anti-TNFÂ antibody treatment in patients with rheumatic diseases. Annals of the Rheumatic Diseases, 2006, 66, 558-559.	0.9	70
22	Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 724-730.	2.0	68
23	Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis and Rheumatology, 2017, 69, 301-308.	5.6	56
24	Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis and Rheumatism, 2002, 46, 3266-3272.	6.7	54
25	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. Journal of Psychosomatic Research, 2012, 72, 199-204.	2.6	54
26	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
27	Total ankle prostheses in rheumatoid arthropathy. Monthly Notices of the Royal Astronomical Society: Letters, 2009, 80, 440-444.	3.3	52
28	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
29	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2017, 56, 1302-1311.	1.9	51
30	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
31	Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opinion on Pharmacotherapy, 2009, 10, 1183-1190.	1.8	47
32	Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial. Annals of the Rheumatic Diseases, 2019, 78, annrheumdis-2018-214104.	0.9	43
33	Nontuberculous mycobacterial bursitis and arthritis of the shoulder. Skeletal Radiology, 1998, 27, 33-35.	2.0	42
34	Fatigue in knee and hip osteoarthritis: the role of pain and physical function. Rheumatology, 2011, 50, 1894-1900.	1.9	41
35	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskeletal Disorders, 2013, 14, 299.	1.9	39
36	Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption. Journal of Cellular Physiology, 2017, 232, 225-233.	4.1	36

#	Article	IF	Citations
37	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders, 2011, 12, 12.	1.9	35
38	Validity of the Fear of Progression Questionnaire–Short Form in patients with systemic sclerosis. Arthritis Care and Research, 2012, 64, 930-934.	3.4	34
39	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology, 2016, 55, 2001-2008.	1.9	34
40	Survivorship of the KUDO total elbow prosthesis– comparative study of cemented and uncemented ulnar components: 89 cases followed for an average of 6 years. Monthly Notices of the Royal Astronomical Society: Letters, 2007, 78, 258-262.	3.3	32
41	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 1191-1196.	0.9	32
42	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non–)response to infliximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2013, 76, 939-945.	2.4	32
43	Eosinophilic fasciitis in a child mimicking a myopathy. Neuromuscular Disorders, 2006, 16, 144-148.	0.6	30
44	Shoulder hemiarthroplasty in rheumatoid arthritis 19 cases reexamined after 1-17 years. Acta Orthopaedica, 1997, 68, 243-245.	1.4	29
45	Poor psychological health status among patients with inflammatory rheumatic diseases and osteoarthritis in multidisciplinary rehabilitation: Need for a routine psychological assessment. Disability and Rehabilitation, 2010, 32, 836-844.	1.8	28
46	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open, 2018, 4, e000654.	3.8	28
47	Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1334-1338.	0.9	26
48	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders, 2012, 13, 184.	1.9	25
49	Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane. Arthritis Research and Therapy, 2016, 18, 186.	3.5	21
50	Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity. Frontiers in Immunology, 2018, 9, 2388.	4.8	21
51	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. Patient Education and Counseling, 2020, 103, 254-265.	2.2	21
52	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatology, 2017, 56, 973-980.	1.9	20
53	High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis. JAMA Dermatology, 2016, 152, 1262.	4.1	19
54	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 349-358.	1.8	19

#	Article	IF	Citations
55	Cost‐Utility and Cost‐Effectiveness Analyses of Face‐to‐Face Versus Telephone‐Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis. Arthritis Care and Research, 2016, 68, 502-510.	3.4	18
56	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	1.6	18
57	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Education and Counseling, 2012, 89, 143-151.	2.2	17
58	Short fatigue questionnaire: Screening for severe fatigue.. Journal of Psychosomatic Research, 2020, 137, 110229.	2.6	17
59	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2260-2261.	0.9	15
60	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients. PLoS ONE, 2013, 8, e53923.	2.5	14
61	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	1.6	14
62	Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Rheumatology, 2022, 61, 2307-2315.	1.9	14
63	Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor Â-neutralising treatments in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 1525-1530.	0.9	13
64	Systemic sclerosis: To subset or not to subset, that is the question. European Journal of Rheumatology, 2020, 7, 222-227.	0.6	13
65	Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis. International Journal of Behavioral Medicine, 2018, 25, 198-206.	1.7	12
66	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the Rheumatic Diseases, 2010, 69, 1655-1659.	0.9	10
67	Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases. Journal of Rheumatology, 2018, 45, 122-127.	2.0	10
68	Most Important Frequently Asked Questions From Patients With Hip or Knee Osteoarthritis: A Best‐Worst Scaling Exercise. Arthritis Care and Research, 2019, 71, 885-892.	3.4	10
69	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. Human Immunology, 2009, 70, 130-133.	2.4	9
70	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	2.0	9
71	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology, 2016, 55, 2023-2032.	1.9	9
72	Preparing for an orthopedic consultation using an eHealth tool: a randomized controlled trial in patients with hip and knee osteoarthritis. BMC Medical Informatics and Decision Making, 2020, 20, 92.	3.0	9

#	Article	IF	Citations
73	Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology, 2020, 59, 1550-1555.	1.9	8
74	Comparison of physical activity among different subsets of patients with knee or hip osteoarthritis and the general population. Rheumatology International, 2020, 40, 383-392.	3.0	8
75	Social Support, Disease-Related Cognitions and Coping as Predictors of Depressed Mood in Systemic Sclerosis. Cognitive Therapy and Research, 2008, 32, 434-447.	1.9	7
76	Effect of naproxen on the hypothalamicâ€"pituitaryâ€" adrenal axis in healthy volunteers. British Journal of Clinical Pharmacology, 2009, 67, 22-28.	2.4	6
77	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. RMD Open, 2017, 3, e000327.	3.8	6
78	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. Rheumatology Advances in Practice, 2018, 2, rky027.	0.7	6
79	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
80	Systemic Sclerosis: New Insights in Autoimmunity. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222, 1-8.	1.8	6
81	An Electronic Health Tool to Prepare for the First Orthopedic Consultation: Use and Usability Study. JMIR Formative Research, 2019, 3, e13577.	1.4	6
82	Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis. Rheumatology, 2010, 49, 588-591.	1.9	5
83	Cognitive-Behavioural Therapy Targeting Fear of Progression in an Interdisciplinary Care Program: A Case Study in Systemic Sclerosis. Journal of Clinical Psychology in Medical Settings, 2014, 21, 297-312.	1.4	4
84	Use and usability of the dr. Bart app and its relation with health care utilisation and clinical outcomes in people with knee and/or hip osteoarthritis. BMC Health Services Research, 2021, 21, 444.	2.2	4
85	Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?. Clinical and Experimental Rheumatology, 2021, 39, 32-37.	0.8	4
86	The mutations in the fibronectin gene described in japanese patients with systemic sclerosis are not present in dutch patients. Arthritis and Rheumatism, 1991, 34, 490-492.	6.7	3
87	Isolation and Characterization of Single Anti-U1A-specific B Cells from Autoimmune Patients. Annals of the New York Academy of Sciences, 1997, 815, 440-442.	3.8	3
88	InforMatrixÂ®: treatment of rheumatoid arthritis using biologicals. Expert Opinion on Pharmacotherapy, 2006, 7, 1769-1789.	1.8	3
89	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	2.0	3
90	Economic evaluation of the dr. Bart app in people with knee and/or hip osteoarthritis. Arthritis Care and Research, 2021, , .	3.4	3

#	ARTICLE	IF	CITATIONS
91	Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER): Protocol for a Longitudinal Observational Study. JMIR Research Protocols, 2021, 10, e31647.	1.0	3
92	What does the clinician need to improve patient care in systemic sclerosis?. Annals of the Rheumatic Diseases, 2007, 66, 1129-1131.	0.9	2
93	Evolving Concepts of Diagnosis and Classification. , 2012, , 53-69.		2
94	Evolving Concepts of Diagnosis and Classification. , 2017, , 49-64.		2
95	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 48-55.	0.8	2
96	Anti-cyclic citrullinated peptide antibody in early rheumatoid arthritis: Comment on the editorial by Scott. Arthritis and Rheumatism, 2003, 48, 857-857.	6.7	1
97	Response to: â€˜Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritisâ€™ by Wu<i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e25-e25.	0.9	1
98	(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 767-8.	0.8	1
99	Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 140-143.	0.8	1
100	Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 367-372.	0.8	1
101	Analysis of antiâ€"U1 RNA antibodies in patients with connective tissue diseases: Comment on the article by Hoffman et al. Arthritis and Rheumatism, 1996, 39, 1265-1266.	6.7	0
102	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. Rheumatology, 2019, , .	1.9	0
103	SAT0259â€...PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
104	SAT0282â€...EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSIONIN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
105	OP0079â€...HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
106	Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e35-e35.	0.9	0
107	Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. Clinical and Experimental Rheumatology, 2019, 37, 414-421.	0.8	0